Reunion Neuroscience (TSE:REUN – Get Rating)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday. They presently have a C$20.00 target price on the stock.
Separately, Roth Capital initiated coverage on Reunion Neuroscience in a research report on Friday, December 16th. They set a “buy” rating and a C$11.00 target price on the stock.
Reunion Neuroscience Stock Performance
Shares of TSE:REUN opened at C$1.77 on Thursday. Reunion Neuroscience has a 52-week low of C$1.08 and a 52-week high of C$13.10.
About Reunion Neuroscience
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.